Corpus overview


MeSH Disease

Human Phenotype



There are no seroprevalence terms in the subcorpus

    displaying 1 - 4 records in total 4
    records per page

    COVID-19 and Ischemic Stroke HP Stroke MESHD

    Authors: Amira Sidig; Khabab Abbasher; Hussien Abbasher; Radi Tofaha Alhusseini; Mohamed Elsayed; Mohammed Abbasher; Sufian Khalid M. N; Khalid Hajnoor; Mohammed Malekaldar; Mutaz F. Digna; Abbasher Hussien; Omer Eladil A. Hamid

    doi:10.21203/ Date: 2020-07-26 Source: ResearchSquare

    Background: SARS-CoV-2 causes COVID-19 disease. It was identified in December 2019 and rapidly evolved into a pandemic. During the outbreak of COVID-19, researches demonstrated its effect on many systems, including the nervous system. In our clinic, we have reported an impact of SARS-CoV-2, causing the ischaemic stroke MESHD stroke HP.Case Report: A 62-year-old Sudanese male TRANS with some comorbidities brought to the A&E with fever HP fever MESHD, chest symptoms MESHD, and acute evolving left-sided hemiplegia HP hemiplegia MESHD power grade 0/5 MRCS with left upper motor neuron facial palsy HP facial palsy MESHD. Investigations: CT brain: right middle cerebral artery MCA infarction MESHD. CT- chest: bilateral ground-glass appearance. COVID-19 Test was positive. elevated D-dimer and C-reactive protein.Discussion: A retrospective study of data from the COVID-19 outbreak in China showed that the incidence of stroke HP stroke MESHD among hospitalized patients was approximately 5%. The fact that COVID-19 is an acute inflammatory condition associated with an increased incidence of fatty plaques formation, injury of the vascular wall, and hypercoagulability HP hypercoagulability MESHD, causing brain infarct MESHD can be a reasonable hypothesis.ConclusionPatients with COVID-19 are at increased risk of thrombo-embolization MESHD, leading to arterial and venous cerebrovascular accident MESHD. This case report enhances the importance of further studies to clarify the relationship between stroke HP stroke MESHD and COVID-19.

    Neurological manifestations associated with COVID-19: a nationwide registry

    Authors: Elodie Meppiel; Nathan Peiffer-Smadja; Alexandra Maury; Imen Bekri; Cecile Delorme; Virginie Desestret; Lucas Gorza; Geoffroy Hautecloque-Raysz; Sophie Landre; Annie Lannuzel; Solene Moulin; Peggy Perrin; Paul Petitgas; Francois Sellal; Adrien Wang; Pierre Tattevin; Thomas de Broucker; - contributors to the NeuroCOVID registry

    doi:10.1101/2020.07.15.20154260 Date: 2020-07-16 Source: medRxiv

    Background: The clinical description of the neurological manifestations in COVID-19 patients is still underway. This study aims to provide an overview of the spectrum, characteristics and outcomes of neurological manifestations associated with SARS-CoV-2 infection MESHD. Methods: We conducted a nationwide, multicentric, retrospective study during the French COVID-19 epidemic in March-April 2020. All COVID-19 patients with de novo neurological manifestations were eligible. Results: We included 222 COVID-19 patients with neurological manifestations from 46 centers throughout the country. Median age TRANS was 65 years (IQR 53-72), and 136 patients (61.3%) were male TRANS. COVID-19 was severe or critical in almost half of the patients (102, 45.2%). The most common neurological diseases MESHD were COVID-19 associated encephalopathy HP encephalopathy MESHD (67/222, 30.2%), acute ischemic cerebrovascular syndrome MESHD (57/222, 25.7%), encephalitis HP encephalitis MESHD (21/222, 9.5%), and Guillain-Barre Syndrome MESHD (15/222, 6.8%). Neurological manifestations appeared after first COVID-19 symptoms with a median (IQR) delay of 6 (3-8) days in COVID-19 associated encephalopathy HP encephalopathy MESHD, 7 (5-10) days in encephalitis HP encephalitis MESHD, 12 (7-18) days in acute ischemic cerebrovascular syndrome MESHD and 18 (15-28) days in Guillain-Barre Syndrome MESHD. Brain imaging was performed in 192 patients (86.5%), including 157 MRI (70.7%). Brain MRI of encephalitis HP encephalitis MESHD patients showed heterogeneous acute non vascular lesion in 14/21 patients (66.7%) with associated small ischemic lesion or microhemorrhages MESHD in 4 patients. Among patients with acute ischemic cerebrovascular syndrome MESHD, 13/57 (22.8%) had multi territory ischemic strokes HP ischemic strokes MESHD, with large vessel thrombosis MESHD in 16/57 (28.1%). Cerebrospinal fluid was analyzed in 97 patients (43.7%), with pleocytosis MESHD in 18 patients (18.6%). A SARS-CoV-2 PCR was performed in 75 patients and was positive only in 2 encephalitis HP encephalitis MESHD patients. Among patients with encephalitis HP encephalitis MESHD, ten out of 21 (47.6%) fully recovered, 3 of whom received corticosteroids (CS). Less common neurological manifestations included isolated seizure HP seizure MESHD (8/222, 3.6%), critical illness neuropathy MESHD (8/222, 3.6%), transient alteration of consciousness (5/222, 2.3%), intracranial hemorrhage HP intracranial hemorrhage MESHD (5/222, 2.3%), acute benign lymphocytic meningitis MESHD meningitis HP (3/222, 1.4%), cranial neuropathy MESHD (3/222, 1.4%), single acute demyelinating lesion MESHD (2/222, 0.9%), Tapia syndrome MESHD (2/222, 0.9%), cerebral venous thrombosis HP cerebral venous thrombosis MESHD (1/222, 0.5%), sudden paraparesis MESHD paraparesis HP (1/222, 0.5%), generalized myoclonus HP myoclonus MESHD and cerebellar ataxia MESHD ataxia HP (1/222, 0.5%), bilateral fibular palsy (1/222, 0.5%) and isolated neurological symptoms ( headache HP headache MESHD, anosmia HP anosmia MESHD, dizziness MESHD, sensitive or auditive symptoms MESHD, hiccups MESHD, 15/222, 6.8%). The median (IQR) follow-up of the 222 patients was 24 (17-34) days with a high short-term mortality rate (28/222, 12.6%). Conclusion: Neurological manifestations associated with COVID-19 mainly included CAE, AICS, encephalitis HP encephalitis MESHD and GBS MESHD. Clinical spectrum and outcomes were broad and heterogeneous, suggesting different underlying pathogenic processes.

    Characteristics of Ischemic Stroke HP Stroke MESHD in COVID-19: A Need for Early Detection and Management

    Authors: Dinesh V. Jillella; Nicholas J. Janocko; Fadi Nahab; Karima Benameur; James G. Greene; Wendy L. Wright; Mahmoud Obideen; Srikant Rangaraju

    doi:10.1101/2020.05.25.20111047 Date: 2020-05-26 Source: medRxiv

    Objective: In the setting of the Coronavirus Disease MESHD 2019 (COVID-19) global pandemic caused by SARS-CoV-2, a potential association of this disease with stroke HP stroke MESHD has been suggested. We aimed to describe the characteristics of patients who were admitted with COVID-19 and had an acute ischemic stroke HP ischemic stroke MESHD ( AIS MESHD). Methods: This is a case series of PCR-confirmed COVID-19 patients with ischemic stroke HP ischemic stroke MESHD admitted to an academic health system in metropolitan Atlanta (USA) between March 24th,2020, and May 5th, 2020. Demographic, clinical, and radiographic characteristics were described. Results: Of 124 ischemic stroke HP ischemic stroke MESHD stroke MESHD patients admitted during this study period, 8 (6.5%) were also diagnosed with COVID-19. The mean age TRANS of patients was 64.3 +/- 6.5 years, 5 (62.5%) male TRANS, mean time from last-normal was 4.8 days [SD 4.8], and none received acute reperfusion therapy. All 8 patients had at least one stroke HP stroke MESHD-associated co-morbidity. The predominant pattern of ischemic stroke HP ischemic stroke MESHD was embolic MESHD; 3 were explained by atrial fibrillation HP atrial fibrillation MESHD while 5 (62.5%) were cryptogenic. In contrast, cryptogenic strokes HP strokes MESHD were seen in 20 (16.1%) of 124 total stroke HP stroke MESHD admissions during this time. Conclusions: In our case series, ischemic stroke HP ischemic stroke MESHD affected COVID-19 patients with traditional stroke HP stroke MESHD risk factors with an age TRANS of stroke HP stroke MESHD presentation typically seen in non-COVID populations. We observed a predominantly embolic pattern of stroke MESHD stroke HP with a higher than expected rate of cryptogenic strokes HP strokes MESHD and with a prolonged median time to presentation and symptom recognition limiting the use of acute reperfusion treatments. These results highlight the need for increased community awareness, early identification, and management of AIS in COVID-19 patients.

    Etiologic Subtypes of Ischemic Stroke HP Ischemic Stroke MESHD in SARS-COV-2 Virus MESHD patients

    Authors: Ketevan Berekashvili; Adam A Dmytriw; Volodomyr Vulkanov; Shashank Agarwal; Amit Khaneja; David Turkel-Parella; Jeremy Liff; Jeffrey Farkas; Thambirajah Nandakumar; Ting Zhou; Jennnifer Frontera; David E Kahn; Sun Kim; Kelly A Humbert; Matthew D Sanger; Shadi Yaghi; Aaron Lord; Karthikeyan Arcot; Ambooj Tiwari

    doi:10.1101/2020.05.03.20077206 Date: 2020-05-08 Source: medRxiv

    Objective: To describe the ischemic stroke HP ischemic stroke MESHD etiopathogenesis related to COVID-19 in a cohort of NYC hospitals. Background: Extra-pulmonary involvement of COVID-19 has been reported in the hepatic, renal and hematological systems. Most neurological manifestations are non-focal but few have reported the characteristics of ischemic strokes HP ischemic strokes MESHD or investigated its pathophysiology. Methods: Over the last 6 weeks, data from four centers in New York City were collected to review the possible ischemic stroke HP ischemic stroke MESHD types seen in COVID-19 positive patients. Their presentation, demographics, other related vascular risk factors, associated laboratory and coagulation markers, as well as imaging and outcomes were collected. Results: In our study, age TRANS range of patients was 25-75 with no significant male TRANS preponderance. 70% presented for acute hospitalization due the stroke HP stroke MESHD. About a fifth did not have common risk factors for ischemic stroke HP ischemic stroke MESHD stroke MESHD like diabetes MESHD and hypertension HP hypertension MESHD. None had history of atrial fibrillation HP atrial fibrillation MESHD or smoking. 50% had poor outcome with four ending in mortality and one in a critical condition due ARDS. All had high Neutrophil/Lymphocyte ratio except one who demonstrated some neurological recovery. In 70% of our cases, D-dimer levels were collected, and all showed mild to severe elevation. None of the emergent large vessel occlusion (LVO) cases had known cardiac risk factors but two out of five were found to have cardiac abnormalities MESHD during the course of their hospitalization. All LVOs had hypercoagulable lab markers especially elevated D-dimer and/or Fibrinogen. The LVO patients were younger and sicker with a median age TRANS of 46 and mean NIHSS of 24 as opposed to non-LVOs with a median age TRANS of 62 and mean NIHSS of 6 respectively. Conclusion: COVID-19 related ischemic MESHD events can be small vessel, branch emboli MESHD or large vessel occlusions. The latter is often associated with either a hypercoagulable state or cardio-embolism MESHD. Patient outcomes were worse when multi-organ or pulmonary system failure MESHD prevailed. Keywords: COVID-19, Acute Ischemic strokes HP Ischemic strokes MESHD, Emergent Large Vessel Occlusion, Mechanical Thrombectomy MESHD

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.



MeSH Disease
Human Phenotype

Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.